Welcome to our dedicated page for Merck & news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & stock.
Merck & Co., Inc. reports news across a global pharmaceutical business known as MSD outside the United States and Canada. Company updates center on human health products for areas such as oncology, cardiometabolic disease and infections; vaccines including Gardasil; and Merck Animal Health medicines, devices and customer-support systems.
Recurring developments include FDA approvals, clinical and regulatory disclosures, research publications, pipeline additions, business development transactions, material agreements, capital-structure updates, governance matters, and operating and financial results. Recent themes include the approved HIV-1 regimen IDVYNSO, investigational programs such as enlicitide decanoate and TERN-701, technology partnerships for research, manufacturing and commercial functions, and animal health digital engagement initiatives.
Organon Finance 1 LLC, a Merck subsidiary, has priced an offering of €1.25 billion in euro senior secured notes and $4.1 billion in U.S. dollar senior secured notes, alongside $2 billion in senior unsecured notes. This move supports the spinoff of Organon & Co. and aims to repay intercompany loans and cover spinoff-related expenses. The notes will close on April 22, 2021, and will be guaranteed by Organon’s subsidiaries post-spinoff. The offering will cater to qualified institutional buyers and non-U.S. investors, complying with U.S. and EU regulations.
Merck (NYSE: MRK) announced that its Phase 3 KEYNOTE-564 trial for KEYTRUDA, an anti-PD-1 therapy, has met its primary endpoint of disease-free survival (DFS) in patients with renal cell carcinoma (RCC) following nephrectomy. An interim analysis showed a statistically significant improvement in DFS compared to placebo. The trial will continue to assess overall survival, a key secondary endpoint. The safety profile of KEYTRUDA remained consistent with previous studies. Results will be presented at a medical meeting and submitted for regulatory review.
Merck (NYSE: MRK) announced that Organon Finance 1 LLC plans to offer euro-denominated senior secured notes due 2028 and U.S. dollar-denominated senior secured and unsecured notes due 2028 and 2031, respectively. The proceeds will be used to repay intercompany loans and cover spinoff expenses from Merck to Organon & Co. Notes offerings will be subject to market conditions and held in escrow until spinoff conditions are met. The spinoff will form Organon, focusing on women's healthcare with a portfolio of over 60 medicines, strong cash flows, and around 10,000 employees.
Merck (NYSE: MRK) has successfully completed its cash tender offer for all outstanding shares of Pandion Therapeutics at $60 per share. Approximately 27.77 million shares, or 88.6% of Pandion's stock, were tendered. Following the tender offer, a merger was completed, making Pandion a wholly-owned subsidiary of Merck. Consequently, Pandion's stock will no longer be traded on Nasdaq. This acquisition aligns with Merck's long-term strategy to enhance its biopharmaceutical portfolio, particularly in addressing challenging diseases.
Merck (NYSE: MRK) announced a definitive agreement for Organon to acquire Alydia Health, a company focused on preventing maternal morbidity and mortality from postpartum hemorrhage. The deal is valued up to $240 million, comprising $215 million upfront and a $25 million contingent payment. This acquisition aims to enhance Organon's strategy in women’s health and expand the market reach of Alydia’s Jada System. The transaction is expected to complete after the planned spinoff of Organon from Merck, anticipated in late Q2 2021.
Merck (NYSE: MRK) received a positive opinion from the CHMP of the EMA to update the European label for KEYTRUDA, its anti-PD-1 therapy. This update incorporates data from KEYNOTE-361, a Phase 3 trial evaluating KEYTRUDA for advanced or metastatic urothelial carcinoma. Although KEYNOTE-361 missed its primary endpoints for progression-free and overall survival, the CHMP affirmed a favorable benefit-risk profile, allowing healthcare providers to better assess patient treatment options.
Merck (NYSE: MRK) received a Complete Response Letter (CRL) from the FDA regarding the supplemental Biologics License Application for KEYTRUDA, intended for high-risk early-stage triple-negative breast cancer treatment. The application, based on data from the KEYNOTE-522 trial, was deferred by the FDA's advisory committee pending additional data. The next interim analysis is slated for Q3 2021. This CRL does not affect existing approvals for KEYTRUDA, which includes treatment for locally recurrent or metastatic TNBC with PD-L1 expression.
Merck (NYSE: MRK) will hold its first-quarter 2021 sales and earnings conference call on April 29 at 8:00 a.m. EDT. This call aims to provide an overview of the company’s performance for the quarter to investors and analysts. A live audio webcast will be accessible via Merck’s website, along with a replay and supplemental financial disclosures. Merck has a long-standing commitment to research and development in healthcare, focusing on areas such as cancer and infectious diseases. Forward-looking statements in this release are subject to risks and uncertainties that could impact actual results.
Merck (NYSE: MRK) has appointed Caroline Litchfield as its new executive vice president and chief financial officer (CFO), effective April 1, 2021. Litchfield, previously the company's treasurer, succeeds Robert M. Davis, who will become president and then CEO on July 1, 2021. Merck's leadership highlights Litchfield's financial expertise and track record as critical for ensuring the company's sustainable financial strength. Her extensive experience within Merck, including leading finance for its largest business, positions her well for this pivotal role.
Merck announced that the FDA has approved KEYTRUDA for treating locally advanced or metastatic esophageal carcinoma in combination with chemotherapy. This approval is based on the Phase 3 KEYNOTE-590 trial, which showed a 27% reduction in the risk of death and a 35% reduction in disease progression compared to chemotherapy alone. KEYTRUDA demonstrated an overall response rate of 45% versus 29% in the control group. Although effective, KEYTRUDA carries risks of severe adverse reactions, requiring careful management.